SG11201808455VA - Formulations comprising recombinant acid alpha-glucosidase - Google Patents
Formulations comprising recombinant acid alpha-glucosidaseInfo
- Publication number
- SG11201808455VA SG11201808455VA SG11201808455VA SG11201808455VA SG11201808455VA SG 11201808455V A SG11201808455V A SG 11201808455VA SG 11201808455V A SG11201808455V A SG 11201808455VA SG 11201808455V A SG11201808455V A SG 11201808455VA SG 11201808455V A SG11201808455V A SG 11201808455VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- cranbury
- new jersey
- glucosidase
- lysosomes
- Prior art date
Links
- 239000002253 acid Substances 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 108010028144 alpha-Glucosidases Proteins 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 title 1
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 5
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 abstract 5
- 102000045921 human GAA Human genes 0.000 abstract 5
- 210000003712 lysosome Anatomy 0.000 abstract 4
- 230000001868 lysosomic effect Effects 0.000 abstract 4
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- 241000699802 Cricetulus griseus Species 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- 244000228957 Ferula foetida Species 0.000 abstract 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 abstract 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 abstract 1
- ZQICGTYUOSVFMN-UHFFFAOYSA-N Iselin Natural products CC1=C(COc2c3ccoc3cc3oc(=O)ccc23)CC(C)(C)CC1 ZQICGTYUOSVFMN-UHFFFAOYSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229960004593 alglucosidase alfa Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 201000004502 glycogen storage disease II Diseases 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315436P | 2016-03-30 | 2016-03-30 | |
| US201762457588P | 2017-02-10 | 2017-02-10 | |
| PCT/US2017/024982 WO2017173060A1 (fr) | 2016-03-30 | 2017-03-30 | Formulations comprenant une alpha-glucosidase acide recombinante |
| US15/473,999 US10512676B2 (en) | 2016-03-30 | 2017-03-30 | Formulations comprising recombinant acid alpha-glucosidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808455VA true SG11201808455VA (en) | 2018-10-30 |
Family
ID=58632586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808455VA SG11201808455VA (en) | 2016-03-30 | 2017-03-30 | Formulations comprising recombinant acid alpha-glucosidase |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10512676B2 (fr) |
| JP (2) | JP7510743B2 (fr) |
| KR (3) | KR102444612B1 (fr) |
| AU (2) | AU2017239641A1 (fr) |
| BR (1) | BR112018069965A2 (fr) |
| CA (1) | CA3019128A1 (fr) |
| CL (1) | CL2018002768A1 (fr) |
| CO (1) | CO2018011349A2 (fr) |
| IL (4) | IL283430B (fr) |
| MX (2) | MX2023003051A (fr) |
| SG (1) | SG11201808455VA (fr) |
| WO (1) | WO2017173060A1 (fr) |
| ZA (2) | ZA201807183B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102444612B1 (ko) * | 2016-03-30 | 2022-09-21 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| NZ760232A (en) | 2017-06-07 | 2023-05-26 | Regeneron Pharma | Compositions and methods for internalizing enzymes |
| CA3149955A1 (fr) | 2019-09-06 | 2021-03-11 | Kumar DHANASEKHARAN | Procede de capture et de purification de produits biologiques |
| WO2023215865A1 (fr) | 2022-05-05 | 2023-11-09 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de pompe |
| WO2024119070A1 (fr) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de pompe à apparition tardive chez des patients pédiatriques |
| WO2024119091A1 (fr) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Méthodes de traitement de la maladie de pompe infantile chez des patients pédiatriques |
| WO2024151982A1 (fr) * | 2023-01-13 | 2024-07-18 | Amicus Therapeutics, Inc. | Constructions de thérapie génique pour le traitement de la maladie de pompe |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
| US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
| US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US20020073438A1 (en) * | 1995-08-02 | 2002-06-13 | Reuser Arnold J. | Methods of purifying human acid alpha-glucosidase |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| EP1030839B1 (fr) | 1997-11-10 | 2004-02-04 | G.D. SEARLE & CO. | Emploi d'iminosucres alkyles pour traiter la resistance multiple aux anticancereux |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| ATE410506T1 (de) | 1998-12-07 | 2008-10-15 | Genzyme Corp | Behandlung der pompeschen krankheit |
| US6545021B1 (en) | 1999-02-12 | 2003-04-08 | G.D. Searle & Co. | Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections |
| JP2003505430A (ja) | 1999-07-26 | 2003-02-12 | ジー・ディー・サール・アンド・カンパニー | デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| DK3108895T3 (en) | 2000-07-18 | 2018-11-26 | Univ Duke | Treatment of glycogen storage disease type II |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| EP1974752B1 (fr) | 2001-04-30 | 2012-09-26 | BioMarin Pharmaceutical Inc. | Cible infracellulaire de protéines thérapeutiques |
| MXPA04003640A (es) | 2001-10-16 | 2005-04-11 | Rxkinetix Inc | Formulaciones de proteina de alta concentracion y metodo de fabricacion. |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7658916B2 (en) | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
| CA2814774C (fr) | 2003-01-31 | 2016-03-22 | Mount Sinai School Of Medicine Of New York University | Therapie combinee destinee au traitement de troubles associes a une carence proteique |
| FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| CA2556245A1 (fr) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Fabrication d'enzymes lysosomales hautement phosphorylees et utilisations associees |
| ATE465250T1 (de) | 2004-02-10 | 2010-05-15 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| EP3782655A1 (fr) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | Procédé pour le traitement de la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés |
| MXPA05010977A (es) * | 2005-10-12 | 2007-04-11 | Abdala Leopoldo Espinosa | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus. |
| AU2007322123A1 (en) | 2006-11-13 | 2008-05-29 | Biomarin Pharmaceutical Inc. | Methods for treating Pompe disease |
| WO2008112525A2 (fr) | 2007-03-09 | 2008-09-18 | Link Medicine Corporation | Traitement des maladies de surcharge lysosomale |
| WO2008134628A2 (fr) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques |
| EP2252288A1 (fr) | 2007-11-21 | 2010-11-24 | Summit Corporation Plc | Traitement de troubles de repliement de protéine |
| WO2009075815A1 (fr) | 2007-12-07 | 2009-06-18 | Duke University | Thérapie génique d'immunomodulation |
| PT3470077T (pt) | 2008-02-12 | 2020-11-30 | Amicus Therapeutics Inc | Método para previsão da resposta ao tratamento farmacológico de doenças com chaperonas |
| JP2011512876A (ja) | 2008-03-12 | 2011-04-28 | アミカス セラピューティックス インコーポレイテッド | 特異的薬理シャペロンを用いたポンペ病の治療および代理マーカーを用いた治療の監視 |
| JP2011517556A (ja) | 2008-03-12 | 2011-06-16 | アミカス セラピューティックス インコーポレイテッド | ポンペ病のための治療選択肢を診断し評価するための検定 |
| WO2010015816A2 (fr) | 2008-08-06 | 2010-02-11 | Summit Corporation Plc | Traitement de troubles de stockage lysosomal et autres maladies protéostatiques |
| WO2010056746A1 (fr) | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Régimes thérapeutiques, régimes posologiques et médicaments stables pour le traitement de la maladie de pompe |
| CN105879047A (zh) | 2008-12-16 | 2016-08-24 | 建新公司 | 寡糖-蛋白缀合物 |
| WO2010118283A1 (fr) | 2009-04-09 | 2010-10-14 | Amicus Therapeutics, Inc. | Méthodes pour prévenir et/ou traiter des troubles du stockage lysosomal |
| ES2569514T3 (es) * | 2009-06-17 | 2016-05-11 | Biomarin Pharmaceutical Inc. | Formulaciones para enzimas lisosómicas |
| WO2011109600A1 (fr) | 2010-03-05 | 2011-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés pour modifier le motif de glycosylation d'un polypeptide |
| US20140186326A1 (en) | 2011-04-22 | 2014-07-03 | William Canfield | Modified acid alpha glucosidase with accelerated processing |
| WO2013013017A2 (fr) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions et procédés pour modifier la glycosylation de substances thérapeutiques pour les troubles du stockage lysosomal |
| JP6320931B2 (ja) | 2011-12-22 | 2018-05-09 | セントジーン アイピー ゲーエムベーハー | リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ |
| KR20140135222A (ko) | 2012-03-07 | 2014-11-25 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| KR20190114003A (ko) * | 2012-03-15 | 2019-10-08 | 옥시레인 유케이 리미티드 | 폼페병의 치료를 위한 방법 및 물질 |
| PT2844279T (pt) | 2012-05-03 | 2021-03-11 | Amicus Therapeutics Inc | Esquema posológico para o tratamento da doença de pompe |
| CA2915127A1 (fr) | 2012-06-06 | 2013-12-12 | Giancarlo PARENTI | Chaperonnes allosteriques et leurs utilisations |
| PT3201320T (pt) | 2014-09-30 | 2024-01-12 | Amicus Therapeutics Inc | Alfa-glucosidase ácida altamente potente com hidratos de carbono intensificados |
| KR102510941B1 (ko) * | 2015-12-30 | 2023-03-20 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병 치료용의 강화된 산 알파-글루코시다제 |
| MX2018011951A (es) * | 2016-03-30 | 2019-02-13 | Amicus Therapeutics Inc | Metodo para seleccionar proteinas recombinantes ricas en m6p. |
| KR102444612B1 (ko) * | 2016-03-30 | 2022-09-21 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
-
2017
- 2017-03-30 KR KR1020187030850A patent/KR102444612B1/ko active IP Right Grant
- 2017-03-30 WO PCT/US2017/024982 patent/WO2017173060A1/fr active Application Filing
- 2017-03-30 IL IL283430A patent/IL283430B/en unknown
- 2017-03-30 IL IL301319A patent/IL301319A/en unknown
- 2017-03-30 KR KR1020237044402A patent/KR20240001291A/ko not_active Application Discontinuation
- 2017-03-30 BR BR112018069965A patent/BR112018069965A2/pt unknown
- 2017-03-30 AU AU2017239641A patent/AU2017239641A1/en not_active Abandoned
- 2017-03-30 KR KR1020227031739A patent/KR102618519B1/ko active Application Filing
- 2017-03-30 JP JP2018551370A patent/JP7510743B2/ja active Active
- 2017-03-30 SG SG11201808455VA patent/SG11201808455VA/en unknown
- 2017-03-30 US US15/473,999 patent/US10512676B2/en active Active
- 2017-03-30 CA CA3019128A patent/CA3019128A1/fr active Pending
-
2018
- 2018-09-27 IL IL261995A patent/IL261995B/en active IP Right Grant
- 2018-09-28 MX MX2023003051A patent/MX2023003051A/es unknown
- 2018-09-28 CL CL2018002768A patent/CL2018002768A1/es unknown
- 2018-09-28 MX MX2023003052A patent/MX2023003052A/es unknown
- 2018-10-24 CO CONC2018/0011349A patent/CO2018011349A2/es unknown
- 2018-10-26 ZA ZA2018/07183A patent/ZA201807183B/en unknown
-
2019
- 2019-10-16 US US16/654,521 patent/US11491211B2/en active Active
- 2019-10-22 ZA ZA2019/06938A patent/ZA201906938B/en unknown
-
2022
- 2022-04-07 JP JP2022063910A patent/JP2022105010A/ja active Pending
- 2022-06-16 IL IL294012A patent/IL294012B2/en unknown
- 2022-11-07 US US18/053,151 patent/US20240066104A1/en active Pending
-
2024
- 2024-05-20 AU AU2024203333A patent/AU2024203333A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL301319A (en) | 2023-05-01 |
| IL261995B (en) | 2021-06-30 |
| IL283430A (en) | 2021-06-30 |
| KR20220130258A (ko) | 2022-09-26 |
| US11491211B2 (en) | 2022-11-08 |
| US20170333534A1 (en) | 2017-11-23 |
| IL261995A (en) | 2018-10-31 |
| CO2018011349A2 (es) | 2019-02-08 |
| ZA201906938B (en) | 2024-02-28 |
| CL2018002768A1 (es) | 2019-01-11 |
| KR20180124120A (ko) | 2018-11-20 |
| US20240066104A1 (en) | 2024-02-29 |
| JP7510743B2 (ja) | 2024-07-04 |
| KR20240001291A (ko) | 2024-01-03 |
| IL294012B2 (en) | 2023-08-01 |
| BR112018069965A2 (pt) | 2019-01-29 |
| IL283430B (en) | 2022-07-01 |
| IL294012A (en) | 2022-08-01 |
| KR102444612B1 (ko) | 2022-09-21 |
| MX2023003051A (es) | 2023-04-05 |
| JP2022105010A (ja) | 2022-07-12 |
| CA3019128A1 (fr) | 2017-10-05 |
| JP2019510068A (ja) | 2019-04-11 |
| US20200171133A1 (en) | 2020-06-04 |
| AU2024203333A1 (en) | 2024-06-20 |
| US10512676B2 (en) | 2019-12-24 |
| IL294012B1 (en) | 2023-04-01 |
| MX2023003052A (es) | 2023-04-05 |
| WO2017173060A1 (fr) | 2017-10-05 |
| KR102618519B1 (ko) | 2023-12-28 |
| ZA201807183B (en) | 2020-01-29 |
| AU2017239641A1 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808455VA (en) | Formulations comprising recombinant acid alpha-glucosidase | |
| SG11201805320XA (en) | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration | |
| SG11201804965SA (en) | Augmented acid alpha-glucosidase for the treatment of pompe disease | |
| SG11201909203WA (en) | Tissue selective transgene expression | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201809029RA (en) | Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy | |
| SG11201804070XA (en) | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a | |
| SG11201811232XA (en) | Treatment of amd using aav2 variant with aflibercept | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201808592PA (en) | Method for selection of high m6p recombinant proteins | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201806340YA (en) | Zika virus vaccine | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201805795WA (en) | Systems and methods for securing and disseminating time sensitive information using a blockchain | |
| SG11201801401UA (en) | A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease | |
| SG11201807286WA (en) | Methods and compositions for transducing lymphocytes and regulated expansion thereof | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201901996UA (en) | Formulations of ( r)-2-amino-3-phenylpropyl carbamate | |
| JP2017537604A5 (fr) |